Evidence map›Paper›PMID 37811375›Full record

ReviewFrontiers in bioengineering and biotechnology2023

Research progress of calcium carbonate nanomaterials in cancer therapy: challenge and opportunity.

Tiantian Liang, Zongqi Feng, Xiao Zhang, Tianfang Li, Tingyu Yang, Lan Yu

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Targeted Cancer Therapy-on-A-Chip.Advanced healthcare materials · 2024
    Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Tiantian Liang *Graduate School, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Zongqi Feng *Clinical Medical Research Center, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia, China.
Xiao ZhangClinical Medical Research Center, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia, China.
Tianfang LiClinical Medical Research Center, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia, China.
Tingyu YangClinical Medical Research Center, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia, China.
Lan YuClinical Medical Research Center, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia, China.
Inner Mongolia People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer has keeping the main threat to the health of human being. Its overall survival rate has shown rare substantial progress in spite of the improving diagnostic and treatment techniques for cancer in recent years. Indeed, such classic strategies for malignant tumor as surgery, radiation and chemotherapy have been developed and bring more hope to the patients, but still been accompanied by certain limitations, which include the challenge of managing large wound sizes, systemic toxic side effects, and harmful to the healthy tissues caused by imprecise alignment with tumors in radiotherapy. Furthermore, immunotherapy exhibits a limited therapeutic effect in advanced tumors which is reported only up to 25%-30%. The combination of nanomaterials and cancer treatment offers new hope for cancer patients, demonstrating strong potential in the field of medical research. Among the extensively utilized nanomaterials, calcium carbonate nanomaterials (CCNM) exhibit a broad spectrum of biomedical applications due to their abundant availability, cost-effectiveness, and exceptional safety profile. CCNM have the potential to elevate intracellular Ca

Indexed as

calcium carbonate nanomaterialscancer treatmentdrug carriernanotechnologypH-responsive

Identifiers

PMID37811375
PMCPMC10551635
OpenAlexW4386921136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.